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Reply: P2Y12-Based Platelet Function
Assays Should be Complemented
With Cyclooxygenase-Dependent
Testing in Framing the
Therapeutic Windows for Dual
Antiplatelet Therapy
We thank Drs. Gasparovic and Petricevic for their interest in our
study (1) and their comments. They strongly suggest that P2Y12-
based platelet function assays should be complemented with cyclo-
oxygenase-dependent testing in framing the therapeutic windows for
dual antiplatelet therapy. We think that this statement is highly
speculative and not supported by the available evidence. Indeed,
aspirin resistance has been extensively discussed as a real entity by
itself and its association with clinical outcomes. First, response to
aspirin assessed by cyclooxygenase-dependent testing has probably
been overestimated due to a problem of compliance, and a previous
study by our group showed that noncompliance was the main
explanation for aspirin resistance, being a rare entity in compliant
patients (2). For ischemic risk, some studies suggest the potential
impact of aspirin resistance on ischemic events (3), but a recent study
assessing the beneﬁt of tailored therapy based on platelet testing of
aspirin response failed to show any signiﬁcant beneﬁt (4). Therefore,
testing aspirin response for ischemic prognosis and increasing aspirin
dose on the basis of the test results is not supported by available ev-
idence. For bleeding risk, as assessed in our study, to our knowledge,
no study has ever linked the variability of aspirin response and
bleeding complications in patients undergoing percutaneous coro-
nary intervention after acute coronary syndrome. Therefore, the
proposal in their letter is not in line with current data available on
platelet monitoring. Also, themajor risk of assessing aspirin response
could be to use a higher dose in some patients, whereas recent evi-
dence clearly showed that a high dose of aspirin does not provide any
ischemic beneﬁt, only a constant increase in bleeding and gastroin-
testinal events (5).
Accordingly, we performed an additional analysis to conﬁrm
previous assumptions. In the present study, aspirin response was
assessed by arachidonic acid–induced platelet aggregation (AA-Ag).
The rate of aspirin resistance was very low, with only 60 patients
(4%) with aspirin resistance deﬁned as AA-Ag above the 30%
threshold previously proposed. We did not observe any relationship
between AA-Ag and the occurrence of bleeding complications in
our population, as suggested by Gasparovic et al. This could also be
explained by the biological proﬁle of aspirin response in 1,082
patients (70%) of patients with AA-Ag ¼ 0%. Indeed, to identify apredictor of bleeding with platelet monitoring, we need to deﬁne
hyperresponse, which is probably impossible with a drug providing 0%
in more than two thirds of the patients with the present test.
We appreciate the suggestions of Drs. Gasparovic and Petricevic;
however, this statement is supported neither by available evidence nor
by the new analysis provided in this letter. Therefore, it was not an
omission, and we believe that does not compromise the robustness of
the presented data. Following the proposal to integrate the aspirin
effect into bleeding risk assessment, the next step might be to use the
new P2Y12 blockers as long-term monotherapy without aspirin as
currently tested in the GLOBAL LEADERS study
(NCT01813435).
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Looking for the Native Annulus
After Transcatheter Aortic Valve
Replacement?
I readwith great interest the recently publishedpaperbyBinder et al. (1)
that described the impact of post-implantation SAPIENXT (Edwards
Lifesciences Inc., Irvine, California) geometry and positioning on
clinical outcome after transcatheter aortic valve replacement (TAVR).
